DNLI Denali Therapeutics, Inc.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Company profile
Ticker
DNLI
Exchange
CEO
Ryan J. Watts
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
SEC CIK
Corporate docs
DNLI stock data
()
Calendar
6 Aug 19
17 Sep 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 4.2M | 4.21M | 125.68M | 1.2M | |
| Net income | -58.34M | -38.99M | 77.53M | -35.37M | |
| Diluted EPS | -0.61 | -0.41 | 0.79 | -0.38 | |
| Net profit margin | -1390% | -927% | 61.69% | -2960% | |
| Operating income | -62.76M | -42.51M | 74.72M | -37.96M | |
| Net change in cash | 23.28M | -37.46M | 33.47M | 10.56M | |
| Cash on hand | 62.94M | 39.66M | 77.12M | 43.65M |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|
| Revenue | 129.16M | NaN | NaN | |
| Net income | -36.24M | -88.19M | -86.65M | |
| Diluted EPS | -0.39 | -5.89 | -13.49 | |
| Net profit margin | -28.06% | NaN% | NaN% | |
| Operating income | -46.37M | -90.14M | -87.43M | |
| Net change in cash | -141.25M | 178.52M | ||
| Cash on hand | 77.12M | 218.38M | 39.85M |
Financial data from company earnings reports
Financial report summary
?Competition
Eisai • Mallinckrodt • Biogen • Astrazeneca • Roche • Shire • Cytokinetics • Sanofi • AbbVie • ProthenaRisks
- Risks Related to Our Business, Financial Condition and Capital Requirements
- Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
- Risks Related to Regulatory Approval and Other Legal Compliance Matters
- Risks Related to Our Reliance on Third Parties
Management Discussion
- * Percentage is not meaningful.
- * Percentage is not meaningful.
- Collaboration Revenue. Collaboration revenue was $4.2 million and $8.4 million for the three and six months ended June 30, 2019, respectively, and $1.6 million and $2.3 million for the three and six months ended June 30, 2018, respectively. The increase in the three months ended June 30, 2019 compared to the three months ended June 30, 2018 was due to $3.5 million of revenue recognized under our Sanofi Collaboration Agreement, partially offset by a decrease in revenue recognized under the Takeda Collaboration Agreement of $0.9 million. The increase in the six months ended June 30, 2019 compared to the six months ended June 30, 2018 was due to $7.0 million of revenue recognized under our Sanofi Collaboration Agreement, partially offset by a decrease in revenue recognized under the Takeda Collaboration Agreement of $0.9 million.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
altogether, Dementia, driven, fined, formation, Franc, Frontotemporal, FTD, granule, half, ineligible, Intraperiod, judge, jury, rheumatoid, shifting, supposed, undisclosed
Removed:
Antitrust, bankruptcy, calculating, comprising, cure, deposit, exact, exercisable, fifty, fourth, hindsight, insolvency, insolvent, liquidity, myeloid, opt, opted, optimized, remedy, requisite, standoff, unanimously
Financial reports
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
12 Mar 19
10-Q/A
2018 Q2
Quarterly report (amended)
6 Dec 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-K/A
2017 FY
Annual report (amended)
13 Jul 18
10-Q
2018 Q1
Quarterly report
11 May 18
10-K
2017 FY
Annual report
19 Mar 18
Current reports
8-K
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
6 Aug 19
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 19
8-K
Denali Therapeutics Reports First Quarter 2019 Financial Results
8 May 19
8-K
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
12 Mar 19
8-K
Other Events
4 Jan 19
8-K
Other Events
19 Nov 18
8-K
Results of Operations and Financial Condition
8 Nov 18
8-K
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
1 Nov 18
8-K
Denali Therapeutics Reports Second Quarter 2018 Financial Results
9 Aug 18
8-K
Denali Therapeutics Announces Positive Clinical Results from LRRK2 Inhibitor Program for Parkinson’s Disease
1 Aug 18
Registration and prospectus
S-3ASR
Automatic shelf registration
13 Mar 19
S-8
Registration of securities for employees
13 Mar 19
424B4
Prospectus supplement with pricing info
8 Dec 17
S-8
Registration of securities for employees
8 Dec 17
S-1/A
IPO registration (amended)
7 Dec 17
8-A12B
Registration of securities on exchange
30 Nov 17
S-1/A
IPO registration (amended)
27 Nov 17
S-1
IPO registration
13 Nov 17
DRS/A
Draft registration statement (amended)
27 Oct 17
DRS/A
Draft registration statement (amended)
13 Oct 17
Other
CT ORDER
Confidential treatment order
25 Mar 19
CT ORDER
Confidential treatment order
21 Feb 19
CT ORDER
Confidential treatment order
19 Nov 18
CT ORDER
Confidential treatment order
17 Jul 18
CT ORDER
Confidential treatment order
8 Dec 17
EFFECT
Notice of effectiveness
7 Dec 17
CORRESP
Correspondence with SEC
4 Dec 17
CORRESP
Correspondence with SEC
4 Dec 17
CORRESP
Correspondence with SEC
27 Nov 17
UPLOAD
Letter from SEC
20 Nov 17